Družba PTC Therapeutics deli pozitivne vmesne podatke iz kliničnega preskušanja PIVOT-HD pri bolnikih s Huntingtonovo boleznijo

June 21, 2023 PDF Version – Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks –– Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes –  – Conference call and webcast to be held June 21st at 8:00 am EDT –  SOUTH Preberi več...

sl_SISlovenian